We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Vertex Pharmaceuticals (VRTX - Free Report) to post quarterly earnings of $4.92 per share in its upcoming report, which indicates a year-over-year increase of 2.5%. Revenues are expected to be $3.4 billion, up 10.6% from the year-ago quarter.
The current level reflects an upward revision of 2.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Vertex metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues by Product- Trikafta/Kaftrio' of $2.49 billion. The estimate indicates a year-over-year change of -6%.
Analysts' assessment points toward 'Revenues by Product- Other CF product revenues' reaching $125.43 million. The estimate indicates a year-over-year change of -28.7%.
Analysts forecast 'Revenues by Product- ALYFTREK' to reach $631.00 million. The estimate indicates a year-over-year change of +155.5%.
It is projected by analysts that the 'Revenues- Product revenues, net' will reach $3.39 billion. The estimate indicates a year-over-year change of +10.1%.
Vertex shares have witnessed a change of -1.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts expect Vertex Pharmaceuticals (VRTX - Free Report) to post quarterly earnings of $4.92 per share in its upcoming report, which indicates a year-over-year increase of 2.5%. Revenues are expected to be $3.4 billion, up 10.6% from the year-ago quarter.
The current level reflects an upward revision of 2.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Vertex metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues by Product- Trikafta/Kaftrio' of $2.49 billion. The estimate indicates a year-over-year change of -6%.
Analysts' assessment points toward 'Revenues by Product- Other CF product revenues' reaching $125.43 million. The estimate indicates a year-over-year change of -28.7%.
Analysts forecast 'Revenues by Product- ALYFTREK' to reach $631.00 million. The estimate indicates a year-over-year change of +155.5%.
It is projected by analysts that the 'Revenues- Product revenues, net' will reach $3.39 billion. The estimate indicates a year-over-year change of +10.1%.
View all Key Company Metrics for Vertex here>>>Vertex shares have witnessed a change of -1.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.2% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .